Q2 2025 Management View Steven O. Vondran, President and CEO, stated that "2025 continues to be a good year." He highlighted ...

Join Jeff Margolin of First Trust on CEF Insights for a 2025 midyear review of closed-end fund (CEF) performance and expert ...

Apple, Microsoft, Amazon and Facebook parent Meta Platforms, four of the "Magnificent Seven," whose stocks heavily influence ...

Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

Shipowners grapple with OPEC+ supply increases, tensions in the Middle East, and rising numbers of newbuildings.

The upgrade for emerging markets reflects a more optimistic outlook globally by the Fund, which nudged global GDP growth ...

Schneider adds that investors seem optimistic about American Tower due to stronger domestic organic growth heading into ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Q2 2025 Management View CEO Zvi Alon stated that Tigo achieved its "sixth increase in sequential quarterly revenue growth, growing 27.7% sequentially and 89.4% on a year-over-year basis." He reported ...

Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...

The IMF on Tuesday raised its global growth forecasts for 2025 and 2026 slightly, citing stronger-than-expected purchases ...

Discover AtriCure's standout Q2 2025 performance with 17% revenue growth, boosted by product innovation and international expansion.